The Warfarin/Aspirin study in heart failure (WASH): A randomized trial comparing antithrombotic strategies for patients with heart failure

American Heart Journal

Volumn 148, Issue 1, 2004, Pages 157-164

  Cleland, J G F ^a   Findlay, I ^b   Jafri, S ^c   Sutton, G ^d   Falk, R ^e   Bulpitt, C ^f   Prentice, C ^g   Ford, I ^h   Trainer, Adele ^h   Poole Wilson, P A ⁱ  

^a UNIVERSITY OF HULL   (United Kingdom)

^b ROYAL ALEXANDRA HOSPITAL   (United Kingdom)

^c HENRY FORD HOSPITAL   (United States)

^d HILLINGDON HOSPITAL   (United Kingdom)

^e BOSTON UNIVERSITY   (United States)

^f HAMMERSMITH HOSPITAL   (United Kingdom)

^g UNIVERSITY OF LEEDS   (United Kingdom)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; DIURETIC AGENT; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DRUG TARGETING; FATALITY; FEASIBILITY STUDY; FEMALE; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STROKE; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ASPIRIN; CARDIOMYOPATHY, DILATED; CEREBROVASCULAR ACCIDENT; FEASIBILITY STUDIES; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; WARFARIN;

EID: 2942564768     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.03.010     Document Type: Article

References (29)

1. Cleland J.G.F. Anticoagulant and antiplatelet therapy in heart failure. Curr Opinion Cardiol. 12:1997;276-287
2. Loh E., Sutton M.S., Wun C.-C.C., et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med. 336:1997;251-257
3. Lip G.Y.H., Gibbs C.R. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J An Coll Cardiol. 33:1999;1424-1426
4. Cleland J.G.F., Massie B.M., Packer M. Sudden death in heart failure vascular or electrical? Eur J Heart Fail. 1:1999;41-45
5. Cleland J.G.F., Bulpitt C.J., Falk R.H., et al. Is aspirin safe for patients with heart failure? Br Heart J. 74:1995;215-219
6. The WASH study steering committee and investigators. The WASH study (Warfarin/Aspirin Study in Heart failure) rationale, design and methods. Eur J Heart Failure. 1:1999;95-99
7. Anderson G.M., Hull E. The effect of dicumarol upon the mortality and incidence of thromboembolitic complications in congestive heart failure. Am Heart J. 39:1950;697-702
8. Griffith G.C., Stragnell R., Levinson D.C., et al. A study of the beneficial effects of anticoagulant therapy in congestive heart failure. Ann Int Med. 37:1952;867-887
9. Harvey W.P., Finch C.A. Dicumarol prophylaxix of thromboembolic disease in congestive heart failure. New Engl J Med. 242:1950;208-211
10. Wishart J.H., Chapman C.B. Dicumarol therapy in congestive heart failure. New Engl J Med. 239:1948;701-704
11. Task Force for the Diagnosis and Treatment of Chronic Heart Failure ESoC. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 22:2001;1527-1560
12. Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacological approaches. J Card Failure. 5:1999;357-382
13. Cleland J.G.F. Is aspirin 'The Weakest Link' in cardiovascular prophylaxis the surprising lack of evidence supporting the use of aspirin for cardiovascular disease. Prog Cardiovasc Dis. 44:2002;275-292
14. Cleland J.G.F., John J., Houghton T. Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors in hypertension or heart failure? Curr Opin Nephrol Hypertens. 10:2001;625-631
15. Teo K.K., Yusuf S., Pfeffer M., et al. Effects of long-term treatment with ACE inhibitors in the presence or absence of aspirin a systematic review. Lancet. 360:2002;1037-1043
16. Flather M.D., Yusuf S., Kober L., et al. Long term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction a systematic overview of data from individual patients. Lancet. 355:2000;1575-1581
17. Cleland J.G.F. For Debate preventing atherosclerotic events with aspirin. BMJ. 324:2002;103-105
18. Cleland J.G.F. No reduction in cardiovascular risk with NSAIDs-including aspirin? Lancet. 359:2002;92-93
19. Davie A.P., Love M.P., McMurray J.J.V. Even low-dose aspirin inhibits arachidonic acid-induced vasodilatation in heart failure. Clin Pharm Ther. 67:2000;530-537
20. Haynes G., Webb D.J. Endothelium-dependent modulation of responses to endothelin-1 in human veins. Clin Sci. 84:1993;427-433
21. Riegger G.A.J., Kahles H.W., Elsner D., et al. Effects of acetylsalicylic acid on renal function in patients with chronic heart failure. Am J Med. 90:1991;571-575
22. Wald N.J., Law M.R. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 326:2003;1407-1408
23. Jones C.G., Cleland J.G.F. Meeting report - LIDO, HOPE, MOXCON and WASH Studies. Eur J Heart Failure. 1:1999;425-431
24. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 348:1996;1329-1339
25. Hansson L., Zanchetti A., Carruthers S.G., et al. Effect of intensive blood pressure lowering and low-dose aspirin in patients with hypertension principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet. 351:1998;1755-1762
26. Aspirin Myocardial Infarction Study Research Group. A randomised, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA. 243:1980;661-668
27. Brambrilla R., Guazzi M., Pontone G., et al. Worsening of morbidity and renal function in angiotensin-converting enzyme-inhibited heart failure patients taking aspirin. Eur J Heart Failure. 3:2001;S60
28. Guazzi M., Brambilla R., Reina G., et al. Aspirin-Angiotensin-Converting Enzyme Inhibitor Coadministration and Mortality in Patients With Heart Failure A dose-related adverse effect of aspirin. Arch Intern Med. 163:2003;1574-1579
29. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for the prevention of death, myocardial infarction and stroke in high risk patients. BMJ. 324:2002;71-86